ストックスクリーナーアプリを入手
2.29
2.97%
-0.07
Dogwood Therapeutics Inc (DWTX) 最新ニュース
Dogwood (DWTX) Update: Records a 6.87% Increase to $2.49 at the Close; Boundary Watch: the Supplied Trading Band Runs From $2.37 to $2.61 in the Latest SessionImpulse Wave - vinanet.vn
Dogwood Therapeutics, Inc. (NASDAQ: DWTX) Stock Price, News & Analysis - Kalkine
Armistice Capital Expands Dogwood Therapeutics Stake Amid Biotec - GuruFocus
Dogwood (DWTX) Earnings Reading: Profit Per Share Clears Its Benchmark in the Current Update; Latest Reaction - vinanet.vn
Research Analysts Offer Predictions for DWTX Q3 Earnings - MarketBeat
Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026 - The Manila Times
Halneuron Has Been Tested on More Than 800 Patients—What’s Next? - Stock Titan
What is HC Wainwright's Forecast for DWTX FY2029 Earnings? - MarketBeat
Dogwood Therapeutics, Inc. 2026: Revenue ($14.06M), EPS ($0.34) — 10-Q Summary - TradingView
Dogwood Therapeutics (DWTX) logs $16.5M H1 loss and warns on going concern outlook - Stock Titan
Armistice Capital (DWTX) discloses 9.99% Dogwood Therapeutics ownership in 13G/A - Stock Titan
Maxim Group Maintains Dogwood Therapeutics(DWTX.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Dogwood Therapeutics (NASDAQ:DWTX) Releases Earnings Results, Misses Estimates By $0.21 EPS - MarketBeat
Form 8K Dogwood Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Dogwood Therapeutics Reports $11.5 Million Second-Quarter Net Loss - Quiver Quantitative
Dogwood Therapeutics reports Q2 2026 net loss of $11.5M, IPR&D charge of $9.19M; $9.6M cash - TradingView
DWTX: Halneuron Phase 2b trial nears completion as Q2 net loss widens on higher R&D and impairment - TradingView
Dogwood Therapeutics Announces Second Quarter 2026 Financial Results - The Manila Times
Dogwood Therapeutics (DWTX) Rises 2.78% as Buyers Defend Key $1.76 SupportMAMA Signal - vinanet.vn
Dogwood Therapeutics Inc (DWTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dogwood Therapeutics Inc (DWTX) Stock News Today - TradingKey
Dogwood Therapeutics Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Dogwood Therapeutics (DWTX) to Release Quarterly Earnings on Wednesday - marketbeat.com
Dogwood Therapeutics (DWTX) Holds Steady at $1.79: Key Levels to Watch as Biotech Stock ConsolidatesDividend Growth Stocks - dars.gov.et
Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 4.3%What's Next? - MarketBeat
Dogwood Therapeutics posts corporate presentation on non-opioid pain, neuropathy drug pipeline - Bitget
Dogwood Therapeutics Inc (DWTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Dogwood Therapeutics Inc. (DWTX) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Surprise - vinanet.vn
Dogwood Therapeutics, Inc. Revenue Breakdown – NASDAQ:DWTX - TradingView
Dogwood Therapeutics Inc (DWTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Dogwood Therapeutics Inc (DWTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
DWTX|Dogwood Therapeutics Inc|Price:1.530|Chg%:+0.030 - TradingKey
Dogwood Therapeutics Market Sentiment - Benzinga España
Dogwood Therapeutics Inc (DWTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
DWTX Q1 2026 Earnings: EPS Beats by 42.7% as Pre-Revenue Biotech Charts Path ForwardDividend Growth Analysis - vinanet.vn
Dogwood Therapeutics Inc (DWTX) Balance Sheet - TradingKey
Dogwood Therapeutics Inc (DWTX) Income Statement - TradingKey
Dogwood Therapeutics Inc (DWTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dogwood Therapeutics Inc. (DWTX) Q1 2026 Earnings: Narrower Net Loss Exceeds Consensus Expectations Amid Clinical DevelopmentGuidance Accuracy Score - dars.gov.et
TradingKey - TradingKey
Dogwood Therapeutics Inc. (DWTX) Q1 2026 Earnings: Narrower-than-Expected Loss Signals Cost Discipline Despite No RevenueProfit Cycle Analysis - Vinanet
Dogwood Therapeutics Enrolls First 200 Patients in Phase 2b Neuropathic Pain Trial - marketscreener.com
Dogwood (DWTX) Reaches Enrollment Milestone in HAL-CINP Phase 2b Trial - GuruFocus
Dogwood Therapeutics enrolls 200 patients in pain treatment trial - Investing.com
Dogwood Reports 4.5% Early Termination Rate Among First 200 Patients - Stock Titan
DWTX Q1 2026 Earnings: Narrower Loss Exceeds Expectations, Stock RisesLow Estimate Range - vinanet.vn
Enterprise value to revenue forward of Dogwood Therapeutics, Inc. – NASDAQ:DWTX - TradingView
Dogwood Therapeutics (DWTX) Slips 1% as Shares Test Support Near $1.36Single Stock ETF - dars.gov.et
Dogwood Therapeutics (DWTX) Slips Modestly, Holds Above Key Support LevelBull Flag - dars.gov.et
Dogwood Therapeutics (DWTX) Edges Higher Amid Tight Trading RangeRSI Overbought Alerts - dars.gov.et
Dogwood Therapeutics (DWTX) Holds Steady at $1.42 – Key Levels in FocusBuffered ETF - dars.gov.et
Virios Therapeutics weighs strategic options as development focus remains on fibromyalgia - Ad-hoc-news.de
Dogwood Therapeutics (DWTX) Rises 4.35% as Stock Climbs Toward Resistance LevelThrowback Trade - dars.gov.et
Price to sales forward of Dogwood Therapeutics, Inc. – NASDAQ:DWTX - TradingView
Enterprise value to EBIT forward of Dogwood Therapeutics, Inc. – NASDAQ:DWTX - TradingView
Price to earnings forward of Dogwood Therapeutics, Inc. – NASDAQ:DWTX - TradingView
DWTXDogwood Therapeutics Inc Latest SEC Filings - Finviz
Dogwood Therapeutics Names OrbiMed’s Iain Dukes Chair of Scientific Advisory Board - citybiz
Dogwood Therapeutics appoints Iain Dukes to lead advisory board - Investing.com
Dogwood Therapeutics appoints Iain Dukes to lead advisory board By Investing.com - Investing.com Nigeria
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board - GlobeNewswire
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):